J
Josu Miren Baraia-Etxaburu
Publications - 3
Citations - 458
Josu Miren Baraia-Etxaburu is an academic researcher. The author has contributed to research in topics: Tuberculin & Methicillin-resistant Staphylococcus aureus. The author has an hindex of 3, co-authored 3 publications receiving 406 citations.
Papers
More filters
Journal ArticleDOI
A Large Multicenter Study of Methicillin–Susceptible and Methicillin–Resistant Staphylococcus aureus Prosthetic Joint Infections Managed With Implant Retention
Jaime Lora-Tamayo,Oscar Murillo,José Antonio Iribarren,Alex Soriano,Mar Sánchez-Somolinos,Josu Miren Baraia-Etxaburu,Alicia Rico,Julián Palomino,Dolors Rodríguez-Pardo,Juan Pablo Horcajada,N. Benito,Alberto Bahamonde,A. Granados,María Dolores del Toro,Javier Cobo,Melchor Riera,Antonio Ramos,Alfredo Jover-Sáenz,Javier Ariza,G. Euba,Xavier Cabo,Salvador Pedrero,Miguel Ángel Goenaga,Maitane Elola,Enrique Moreno,Sebastián García-Ramiro,J.C. Martínez-Pastor,Eduard Tornero,Juan M. García-Lechuz,Mercedes Marín,Manuel Villanueva,Iñigo López,Ramón Cisterna,Juan Miguel Santamaría,M. Gomez,Andres Puente,Pedro Cano,Carlos Pigrau,Roger Sordé,Xavier Flores,Luisa Sorlí,Paula González-Miguez,Lluís Puig,María Franco,Marcos Jordán,Pere Coll,Juan Amador-Mellado,Carlos Fuster-Foz,Luis García-Paíno,Isabel Nieto,Miguel A. Muniain,Ana-Isabel Suárez,María Antonia Maseguer,Eduardo Garagorri,Vicente Pintado,Carmen Marinescu,Antonio Ramírez,Elena Múñez,Teresa Álvarez,Rodrigo García,Fernando Barcenilla,Laura Iogna Prat,Ferran Pérez +62 more
TL;DR: The use of rifampin may have contributed to homogenizing MSSA and MRSA prognoses, although the specific rifampsin combinations may have had different efficacies.
Journal ArticleDOI
Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated With Highly Active Antiretroviral Therapy
Juan Berenguer,Pilar Miralles,Julio Arrizabalaga,Esteban Ribera,Fernando Dronda,Josu Miren Baraia-Etxaburu,Pere Domingo,Manuel Márquez,F Rodríguez-Arrondo,Fernando Laguna,Rafael Rubio,José Lacruz Rodrigo,José Mallolas,Verónica de Miguel,Gesida +14 more
TL;DR: One-third of patients with PML died despite receipt of HAART; neurologic function improved in approximately one-half of the survivors; a CD4+ cell count of <100 cells/microL was associated with higher mortality.